This startup develops a precision molecular biomarker test that analyzes blood-immune system communication to rapidly and accurately diagnose sepsis. Their platform uses transcriptomics, metabolomics, lipidomics, AI, and machine learning to identify host-response biomarkers, enabling healthcare providers to quickly diagnose and treat life-threatening conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Sepsis, a life-threatening condition resulting from the body's overwhelming response to an infection, leads to widespread inflammation, organ damage, and a high mortality rate. Current diagnostic methods, such as blood culture tests, can take up to two days, delaying timely intervention and negatively impacting patient outcomes, especially in neonatal cases where large blood volumes are problematic. The lack of rapid and accurate diagnostic tools hinders effective treatment and contributes to the high global sepsis-related death toll.
Solution
Profionics is developing a precision molecular biomarker test that enables rapid and accurate sepsis diagnosis by decoding the communication from the blood-immune system. The test analyzes 52 patient-invariant biomarkers, encompassing inflammatory, metabolic, and adaptive pathways, using a combination of transcriptomics, metabolomics, and lipidomics. By integrating these "omics" technologies with artificial intelligence and machine learning, the platform compares results against established reference values to diagnose sepsis in under 30 minutes, requiring only 50 uL of whole blood. This host-response analysis offers a faster alternative to traditional blood culture tests and demonstrates predictive value in identifying infection in blood-culture negative neonatal sepsis cases.
Target Audience
The primary target audience includes healthcare providers, hospitals, and clinical laboratories seeking a rapid and accurate diagnostic test for sepsis, particularly for neonatal patients and cases where timely intervention is critical.
Features
- Host-response analysis of 52 patient-invariant biomarkers
- Integration of transcriptomics, metabolomics, and lipidomics for comprehensive analysis
- AI and machine-learning algorithms for accurate diagnosis
- Rapid results in under 30 minutes
- Requires only 50 uL of whole blood
- Predictive value in identifying infection in blood-culture negative neonatal sepsis cases